mbs-cov
Nucleic acidexperimental
Clinical trial activity
2 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 7, 2022 (NCT05677893)
Timeline
No events for the selected filters.
Indications
Studied for
Mechanism of action
- SARS-CoV-2ANTISENSE INHIBITOR
antisense inhibitor - sars-cov-2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05941793 | Phase 2 | Sep 11, 2023 | — |
| NCT05677893 | Phase 1 | Nov 7, 2022 | — |
Showing 2 of 2 trials
Page 1 / 1